30 results
Diuretic Electrolyte Excretion Effects 
Diuresis, Na+, K+, Mg2+, Ca2+, Cl-, HCO3-, Uric Acid
 - Thiazide Type
Diuretic Electrolyte ... Excretion Effects Diuresis ... +, Mg2+, Ca2+, Cl ... electrolytes #effects #pharmacology ... #comparison #table
Pharmacology of diuretics

Acetazolamide, Loop diuretics, Thiazide‐like diuretics, MRA, Amiloride

Site of Action, Maximum Dose, Half-Life, Onset, Bioavailability,
Pharmacology of ... , Loop diuretics ... #Pharmacology # ... Comparison #Table ... CHF #Cardiology #Management
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
Pharmacokinetics of commonly used diuretics medications in CKD, Cirrhotic Ascites, and Heart Failure
 • Furosemide
 •
commonly used diuretics ... Spironolactone MCW ... MCW_Nephrology #diuretics ... #pharmacology # ... Pharmacokinetics #halflife #comparison
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
Diuretics and Agents Regulating Renal Excretion

Carbonic Anhydrase Inhibitors (Acetazolamide, Dichlorphenamide)
 • Glaucoma
 • Epilepsy
 • Altitude
Diuretics and Agents ... irrigation • Management ... Inhibitors of Na+K+2Cl ... Symport (Loop Diuretics ... #Nephrology #Pharmacology
Vasopressors Table 
Rough properties by Target Receptor, Heart Rate/Inotropy, Systemic Vascular Resistance, Cardiac Output, Blood Pressure,
Dobutamine 2-20 mcg ... Epinephrine 0-20 mcg ... Properties #Table #Pharmacology ... #Effect #Management ... #Comparison #Inotropes
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
100 cells/mm3 g/mL ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
if MIC<0.12 ug/ml ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
suspension 4–6 mL ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology